In the secondary analysis, the less conservative but clinically meaningful criterion of secure reaction (outlined as a fifty% or more reduction in MADRS from baseline for two weeks) was used. In the patients who obtained steady reaction, 25.eight% during the esketamine group and 57.six% during the placebo group relapsed, with https://arthurc925ssl5.wikibyby.com/user